Wednesday, January 27, 2016

Lilly, Roche Diagnostics partner to develop cerebrospinal fluid assay for amyloid-beta 1-42

Eli Lilly and Company today announced an arrangement to partner with Roche Diagnostics on its ongoing development of a commercially scalable cerebrospinal fluid assay for amyloid-beta 1-42.

from Dementia Big http://ift.tt/20u4D3J
via Stopping Dementia



from WordPress http://ift.tt/1VtI5wD
via alcoholic dementia
http://ift.tt/1Tp2GU0

No comments:

Post a Comment